Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD

SZSE:300534 Stock Report

Market Cap: CN¥2.5b

Gansu Longshenrongfa Pharmaceutical IndustryLTD Valuation

Is 300534 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300534 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300534 (CN¥8.23) is trading below our estimate of fair value (CN¥21.78)

Significantly Below Fair Value: 300534 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300534?

Other financial metrics that can be useful for relative valuation.

300534 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.3x
Enterprise Value/EBITDA17.5x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 300534's PE Ratio compare to its peers?

The above table shows the PE ratio for 300534 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average79x
600721 Xinjiang Bai Hua Cun Pharma TechLtd
85.7xn/aCN¥2.3b
605177 Zhejiang East Asia Pharmaceutical
24.2xn/aCN¥3.0b
600513 Jiangsu Lianhuan Pharmaceutical
19.4xn/aCN¥2.7b
002898 Sailong Pharmaceutical GroupLtd
186.8xn/aCN¥1.8b
300534 Gansu Longshenrongfa Pharmaceutical IndustryLTD
39.1xn/aCN¥2.5b

Price-To-Earnings vs Peers: 300534 is good value based on its Price-To-Earnings Ratio (39.1x) compared to the peer average (79x).


Price to Earnings Ratio vs Industry

How does 300534's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.2%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.2%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 300534 is expensive based on its Price-To-Earnings Ratio (39.1x) compared to the CN Pharmaceuticals industry average (31.3x).


Price to Earnings Ratio vs Fair Ratio

What is 300534's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300534 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio39.1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 300534's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.